Nov-Dec 2012;30(6):954-961
Protocol for expansion of an existing national monthly survey of smoking behaviour and alcohol use in England to Scotland and Wales: the Smoking and Alcohol Toolkit Study
CagriSema is composed of the GLP-1 RA semaglutide and the long-acting insulin analog cagrilintide, and can be administered subcutaneously once a week.117 Beinaglutide Beinaglutide was the first original drug approved for the treatment of obesity in China and the third GLP-1 class reduction drug approved worldwide, and it represents a new treatment option for overweight and obese patients.67,118,119 Beinaglutide, a recombinant human GLP-1 (rhGLP-1) polypeptide, exhibits a remarkable resemblance to human GLP-1(7-36), with nearly 100% homology.120 This innovative compound demonstrates dose-dependent efficacy in regulating glycemic control, suppressing appetite, delaying gastric emptying, and facilitating weight reduction.121 Consequently, beinaglutide holds significant promise for advancing research in the areas of overweight/obesity and nonalcoholic steatohepatitis (NASH).67,122 Beinaglutide is a natural human GLP-1(7-36)-NH2 expressed in Escherichia coli
These waste products are eliminated from the body through the lungs and kidneys, respectively
The goal has always been lasting change, not a quick fix
Thus far, the only detailed data available on the use of the peptide comes from a single group in Russia, albeit from a well-respected one
